Inhibition of the spontaneous polymorphic transition of pyrazinamide γ form at room temperature by co-spray drying with 1,3-dimethylurea

International Journal of Pharmaceutics

Volumn 479, Issue 1, 2015, Pages 163-170

  Baaklini, G ^a   Dupray, V ^a   Coquerel, G ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

1,3 Dimethylurea Co spray drying; Physical stability; Polymorphic transition; Pyrazinamide

Indexed keywords

1,3 DIMETHYLUREA; ARGININE; BETA CYCLODEXTRIN; CITRIC ACID; EXCIPIENT; GLUCOSE; GLYCINE; LACTOSE; MANNITOL; POVIDONE; PYRAZINAMIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; 1,3-DIMETHYLUREA; METHYLUREA; TUBERCULOSTATIC AGENT;

ARTICLE; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; HIGH TEMPERATURE; LOW TEMPERATURE; PHASE TRANSITION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; ROOM TEMPERATURE; SOLID; SPRAY DRYING; STORAGE; STORAGE TEMPERATURE; SURFACE PROPERTY; THERMOGRAPHY; X RAY ANALYSIS; CHEMISTRY; CRYSTALLIZATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; POWDER DIFFRACTION; PROCEDURES; SCANNING ELECTRON MICROSCOPY; TEMPERATURE; X RAY DIFFRACTION;

ANTITUBERCULAR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; METHYLUREA COMPOUNDS; MICROSCOPY, ELECTRON, SCANNING; POVIDONE; POWDER DIFFRACTION; PYRAZINAMIDE; SPECTRUM ANALYSIS, RAMAN; TEMPERATURE; X-RAY DIFFRACTION;

EID: 84920812279     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.12.063     Document Type: Article

References (18)

1. S. Airaksinen, M. Karjalainen, N. Kivikero, S. Westermarck, A. Shevchenko, J. Rantanen, and J. Yliruusi Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation AAPS PharmSciTech 6 2005 311 E322
2. R.A.E. Castro, T.M.R. Maria, A.O.L. Évora, J.C. Feiteira, M.R. Silva, A.M. Beja, J. Canotilho, and M.E.S. Eusébio A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships Cryst. Growth Des. 10 2010 274 282
3. S. Cherukuvada, R. Thakuria, and A. Nangia Pyrazinamide polymorphs: relative stability and vibrational spectroscopy Cryst. Growth Des. 10 2010 3931 3941
4. G. Coquerel Thermodynamic predictions of physical properties - prediction of solid solutions in molecular solutes exhibiting polymorphism Chem. Eng. Technol. 29 2006 182 186
5. G. Coquerel The 'structural purity' of molecular solids - an elusive concept? Chem. Eng. Process. 45 2006 857 862
6. B. Ewen, G.R. Strobl, and D. Richter Phase transitions in crystals of chain molecules. Relation between defect structures and molecular motion in the four modifications of n-C33H68 Faraday discuss Chem. Soc. 69 1980 19 31
7. D. Maher, P. Chaulet, S. Spinaci, and A. Harries Treatment of Tuberculosis: Guidelines for National Programmes 1997 World Health Organization Geneva
8. D. Martins, C. Spanswick, D. Middlemiss, N. Abbas, C. Pulham, and C. Morrison A new polymorph of N,N'-dimethylurea characterized by X-ray diffraction and first-principles lattice dynamics calculations J. Phys. Chem. A 113 2009 5998 6003
9. S.L. Morissette, O. Almarsson, M.L. Peterson, J.F. Remenar, M.J. Read, A.V. Lemmo, S. Ellis, M.J. Cima, and C.R. Gardner High-Throughput Crystallization: Polymorphs, Salts, Co- crystals and Solvates of Pharmaceutical Solids Adv. Drug Deliv. Rev. 56 2004 275 300
10. C. Näther, C. Döring, I. Jess, P.G. Jones, and C. Taouss Thermodynamic and structural relationships between the two polymorphs of 1,3-dimethylurea Acta Crystallogr. 69 2013 70 76
11. D.-D. Pham, E. Fattal, N. Ghermani, N. Guiblin, and N. Tsapis Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients Int. J. Pharm. 454 2013 668 677
12. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19
13. SIDS Initial Assessment Report for SIAM 17, 2003. 11-14 November. Arona, Italy http://www.inchem.org/documents/sids/sids/96311.pdf.
14. Y. Takaki, Y. Sasada, and T. Watanabé The crystal structure of α pyrazinamide Acta Crystallogr. 13 1960 693 702
15. B. Volker Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone 2005 Springer Berlin, Heidelberg, New York 1 254
16. N. Wahlberg, P. Ciochon, V. Petricek, and A. Madsen ∅ Polymorph stability prediction: on the importance of accurate structures: a case study of pyrazinamide Cryst. Growth Des. 14 2013 381 388
17. K.H. Wu, Y.R. Wang, and W.H. Hwu FTIR and TGA studies of poly(4-vinylpyridine-co-divinylbenzene)-Cu(II) complex Polym. Degrad. Stab. 79 2003 195 200
18. Y. Zhang, and D. Mitchison The curious characteristics of pyrazinamide Int. J. Tuberc. Lung Dis. 7 2003 6 21